Lenz & Staehelin represented Samsung Bioepis – part of the Samsung Bioepis group, the developer of the biosimilar Pyzchiva – in a patent nullity proceedings before the Swiss Federal Patent Court. On 12 August 2025, the Court upheld a
Tags :Thierry Calame
Swiss law firm Lenz & Staehelin has appointed a team of four partners to form the newly elected National Management Committee. The team consisting of partners (pictured from left to right)) Heini Rüdisühli,
